Filkri (filgrastim-laha)
/ Intas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 17, 2026
FDA Approves FILKRI (filgrastim-laha), Accord BioPharma’s Biosimilar to NEUPOGEN (filgrastim)
(PRNewswire)
- "...Approved...for patients with cancer receiving myelosuppressive chemotherapy; patients with acute myeloid leukemia receiving induction or consolidation chemotherapy; patients with cancer undergoing bone marrow transplantation; patients with severe chronic neutropenia; and patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)....FILKRI was approved based on two randomized studies in healthy adults, with pharmacokinetics (PK)/pharmacodynamics (PD) assessed in one study and safety and immunogenicity evaluated in both, compared with reference product NEUPOGEN."
FDA approval • Neutropenia
1 to 1
Of
1
Go to page
1